Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. 1993

P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
Laboratoire d'Anatomie Pathologique, Hôpital Antoine Beclere, Clamart, Paris, France.

In a semiquantitative assessment of the expression of transforming growth factor (TGF) beta 1 in liver biopsy specimens from patients with chronic hepatitis C, treatment with interferon alfa-2b (3 million units (MU) three times weekly) decreased the expression of TGF beta 1 in six of seven patients. The reduction in TGF beta 1 correlated significantly with the scores for inflammation (p < 0.05) and necrosis (p < 0.05), but not with the alanine aminotransferase activities (p = 0.36) or the score for fibrosis (p = 0.86).

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
January 1997, Journal of viral hepatitis,
P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
November 1998, Journal of medical virology,
P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
December 2000, The Korean journal of internal medicine,
P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
October 2003, Journal of gastroenterology and hepatology,
P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
November 2014, Hepatology (Baltimore, Md.),
P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
October 1995, Hepatology (Baltimore, Md.),
P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
July 1998, Journal of gastroenterology and hepatology,
P Bedossa, and T Poynard, and P Mathurin, and G Lemaigre, and J C Chaput
February 1995, Journal of hepatology,
Copied contents to your clipboard!